Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) continues to add numerous U.S. and Australian patents to its existing portfolio. Among these is the company’s recent filing for a new transdermal application of cannabidiol (CBD) that followed successful laboratory evaluation of DehydraTECH delivery results. An article discussing the company reads: “LXRP is a British Columbia-based, cannabis-focused food bioscience company, and it is a technology disrupter for edible cannabinoids. Its DehydraTECH technology aids in the body’s absorption of cannabinoids. … The company’s most recent patent filing follows successful laboratory evaluation of DehydraTECH in the transdermal delivery of cannabidiol (CBD). Results showed an increase of up to 225 percent in permeability when compared to control formulations from leading commercial penetration enhancers. The company indicates that it will begin third-party licensing discussions for this new transdermal application as soon as possible, and, based upon past experience, it expects the patent to be formalized within 100 days.”
To view the full article, visit http://cnw.fm/7JbdH
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the U.S. and Australia for utilization of its DehydraTECH™ delivery technology. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits for orally administered bioactive molecules, including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit the company’s website at www.LexariaBioscience.com
More from CannabisNewsBreaks
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
For more information please visit https://www.CannabisNewsWire.com